

Child/Young Person's Name

DOB

Address

NHS Number

The above named child/young person has been identified as being eligible for Covid-19 vaccination in the 12-15 years clinically extremely vulnerable category or living with someone with immunosuppression.

Category of eligibility (as outlined in Green Book):

What should we do before attending?

Please read this leaflet:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1010600/PHE_12073_COVID-19_guide_for_CYP_leaflet.pdf

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1013193/PHE_12124_COVID-19_vaccination_for_at_risk_CYP_simple_text_leaflet.pdf (EASY READ)

There is also a short, animated video which talks through the vaccination process:

<https://vimeo.com/593239243/701ff053cf>

Please ensure the child/young person is well hydrated and has been fed.

Where can they be vaccinated?

If the child/young person attends a special school in Cambridgeshire and Peterborough, you will be contacted by their school offering a date for vaccination in the school setting in September 2021. Consent and medical screening paperwork will be sent to you to complete and return on the day of vaccination.

Otherwise from, 10 September 2021, they can walk-in without booking to one of the large scale Vaccination Centres, across Cambridgeshire and Peterborough. They should be accompanied by someone with parental responsibility. For details of available sites, please look here: <https://www.thevaccinators.co.uk/>

If you are concerned that your child/young person will not cope with the large scale vaccination centre environment and they do not attend a special school, please contact us on ccs.covidmassvacs@nhs.net and the large scale vaccination team will explore with you how they might best be supported.

You will be required to present this letter when attending for appointment as proof of eligibility.

Kind Regards,

Green Book eligibility Criteria for Children/young people 12-15 years who are extremely clinically vulnerable or living in a household with someone who is immunosuppressed

Severe neuro-disability and/or neuromuscular conditions that compromise respiratory function. This includes conditions (such as cerebral palsy, autism and muscular dystrophy) that may affect swallowing and protection of the upper airways, leading to aspiration, and reduce the ability to cough and resulting overall in increased susceptibility to respiratory infections

Children and young adults with learning disability (LD) including individuals with Down's syndrome, those who are on the learning disability register, those with profound and multiple learning disabilities (PMLD) or severe LD.

Immunosuppression due to disease or treatment including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).

Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors.

Individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil, individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg per day (or for children under 20kg body weight a dose of 1mg/kg or more per day).

Anyone with a history of haematological malignancy including leukaemia, lymphoma, and myeloma and those with auto-immune diseases who may require long term immunosuppressive treatments.

Individuals aged over 12 years who are household contacts of immunosuppressed individuals

Those aged 12 years and above who expect to share living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals of any age who are immunosuppressed (as defined below).

Immunosuppression due to disease or treatment including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).

Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.

Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.

Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma and those with systemic lupus erythematosus and rheumatoid arthritis, and psoriasis who may require long term immunosuppressive treatments.